Abstract
Background and Aims Chronic hepatitis C virus (HCV) infection can be cured with direct-acting antiviral agents (DAA). However, not all sequelae of chronic hepatitis C appear to be completely reversible after sustained virologic response (SVR). Recently, chronic viral infections have been shown to be associated with biological age acceleration defined by the epigenetic clock. The aim of this study was to investigate whether chronic HCV infection is associated with epigenetic changes and biological age acceleration and whether this is reversible after SVR.
Methods We included 54 well-characterized patients with chronic hepatitis C at three time points: DAA treatment initiation, end of treatment, and long-term follow-up (median 96 weeks after end of treatment). Genome-wide DNA methylation status from peripheral blood mononuclear cells (PBMC) was generated and used to calculate epigenetic age acceleration (EAA) using Horvath’s clock.
Results HCV patients had an overall significant EAA of 3.12 years at baseline compared with -2.61 years in the age-matched reference group (p<0.00003). HCV elimination resulted in a significant long-term increase in DNA methylation dominated by hypermethylated CpGs in all patient groups. Accordingly, EAA decreased to 1.37 years at long-term follow-up. The decrease in EAA was significant only between the end of treatment and follow-up (p=0.01). Interestingly, eight patients who developed hepatocellular carcinoma after SVR had the highest EAA and showed no evidence of reversal after SVR.
Conclusions Our data contribute to the understanding of the biological impact of HCV elimination after DAA and demonstrate that HCV elimination can lead to “reverse inflammaging”. In addition, we provide new conceptual ideas for the use of biological age as a potential biomarker for HCV sequelae after SVR.
Lay Summary Chronic hepatitis C virus infection is now curable with direct acting antiviral agents (DAA), but are concomitant and sequelae also fully reversible after cure? Recent data demonstrate that chronic viral infections lead to an increase in biological age as measured by epigenetic DNA methylation status. Using a unique cohort of hepatitis C patients with and without cirrhosis as well as progression to HCC, we demonstrated that these epigenetic changes and concomitant increase in biological age are also observed in chronic HCV infection. Our data further suggest that this effect seems to be partially reversible in the long-term course after sustained virological response (SVR) by DAA therapy and that biological regeneration occurs. In this regard, the recovery effect appears to be dependent on disease course and was significantly lower in patients with progression to HCC. This suggests the use of biological age based on epigenetic state as a potential biomarker for HCV sequelae.
Highlights
- Patients with chronic hepatitis C have accelerated epigenetic age compared with healthy controls.
- DAA treatment and HCV elimination partially reverse the accelerated epigenetic age in the long-term follow-up.
- Patients who developed hepatocellular carcinoma after HCV elimination did not show reversal of accelerated epigenetic aging during the follow-up.
Competing Interest Statement
MC reports personal fees from Abbvie, personal fees from Falk Foundation, personal fees from Gilead, personal fees from GlaxoSmithKline, personal fees from Jansen-Cilag, personal fees from Merck/MSD, personal fees from Novartis, personal fees from Roche, personal fees from Spring Bank Pharmaceuticals, and personal fees from Swedish Orphan Biovitrum, outside the submitted work BM reports personal fees from Abbott, personal fees from Abbvie, personal fees from Astellas, personal fees from Bristol-Myers Squibb, personal fees from Falk Foundation, personal fees from Fujirebio, personal fees from Gilead, personal fees from Jansen-Cilag, personal fees from Merck/MSD, personal fees from Norgine, personal fees from Roche, outside the submitted work HW reports grants and personal fees from Abbvie, grants, personal fees and non-financial support from Abbott, grants, personal fees and non-financial support from Roche Diagnostics, personal fees from Siemens, grants and personal fees from BMS, grants and personal fees from Gilead, grants and personal fees from Novartis, grants and personal fees from Roche, personal fees from Janssen, grants and personal fees from Merck/MSD, grants and personal fees from Eiger, grants and personal fees from Falk and Falk Foundation, other from Transgene, non-financial support and other from Myr-GmbH, outside the submitted work CX, YM, ZL, JM, JT, MU, JD, AK, CO have nothing to disclose.
Funding Statement
This project is part of project A5 in the Collaborative Research Center 900 - Microbial Persistence and its Control. CO was supported by a grant from the KlinStrucMed program of Hannover Medical School, funded by the Else Kroener-Fresenius Foundation. Additional infrastructural support (MC) was provided by the German Center for Infection Research, DZIF (TTU 05.708_00, TTU-IICH-07-808). Sequencing costs were co-funded by DZIF (TTU 05.708_01). CX was supported by the Helmholtz Initiative and Networking Fund (1800167). ZL was supported by a grant from the China Scholarship Council.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol conformed to the ethical guidelines of the Declaration of Helsinki and the local ethics committee (Hannover Medical School) approved this study a priori (Nr. 9474_BO_K_2020).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* shared last authorship
Conflicts of interest: MC reports personal fees from Abbvie, personal fees from Falk Foundation, personal fees from Gilead, personal fees from GlaxoSmithKline, personal fees from Jansen-Cilag, personal fees from Merck/MSD, personal fees from Novartis, personal fees from Roche, personal fees from Spring Bank Pharmaceuticals, and personal fees from Swedish Orphan Biovitrum, outside the submitted work
BM reports personal fees from Abbott, personal fees from Abbvie, personal fees from Astellas, personal fees from Bristol-Myers Squibb, personal fees from Falk Foundation, personal fees from Fujirebio, personal fees from Gilead, personal fees from Jansen-Cilag, personal fees from Merck/MSD, personal fees from Norgine, personal fees from Roche, outside the submitted work
HW reports grants and personal fees from Abbvie, grants, personal fees and non-financial support from Abbott, grants, personal fees and non-financial support from Roche Diagnostics, personal fees from Siemens, grants and personal fees from BMS, grants and personal fees from Gilead, grants and personal fees from Novartis, grants and personal fees from Roche, personal fees from Janssen, grants and personal fees from Merck/MSD, grants and personal fees from Eiger, grants and personal fees from Falk and Falk Foundation, other from Transgene, non-financial support and other from Myr-GmbH, outside the submitted work
CX, YM, ZL, JM, JT, MU, JD, AK, CO have nothing to disclose.
Financial support statement: This project is part of project A5 in the Collaborative Research Center 900 - Microbial Persistence and its Control.
CO was supported by a grant from the KlinStrucMed program of Hannover Medical School, funded by the Else Kröner-Fresenius Foundation. Additional infrastructural support (MC) was provided by the German Center for Infection Research, DZIF (TTU 05.708_00, TTU-IICH-07-808). Sequencing costs were co-funded by DZIF (TTU 05.708_01). CX was supported by the Helmholtz Initiative and Networking Fund (1800167). ZL was supported by a grant from the China Scholarship Council.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Abbreviations
- ALT
- Alanine amino transferase
- AST
- Aspartate aminotransferase
- CpG
- 5’-C-phosphate-G-3’
- DAA
- Direct-acting antiviral
- DMSO
- Dimethyl sulfoxide
- DNA
- Deoxyribonucleic acid
- DNAm
- Deoxyribonucleic acid methylation
- EAA
- Epigenetic age acceleration
- FCS
- Fetal calf serum
- GALAD
- Gender, age, AFP-L3, AFP and Des-carboxy-prothrombin (DCP)
- GGT
- Gamma-glutamyl transferase
- HBV
- Hepatitis B virus
- HCC
- Hepatocellular carcinoma
- HCV
- Hepatitis C virus
- HIV
- Human immunodeficiency virus
- INR
- International normalized ratio
- PBMC
- Peripheral blood mononuclear cell
- PS
- Propensity score
- RNA
- Ribonucleic acid
- RPMI
- Roswell Park Memorial Institute medium
- SNP
- Single-nucleotide polymorphism
- SOP
- Standard Operation Procedure
- SVR
- Sustained virological response